NCT07409272 2026-04-16
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Astellas Pharma Inc
Phase 3 Recruiting
Clinical Trials
18 trialsNCT05945823 2026-04-09
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Taiho Oncology, Inc.
Phase 2 Active not recruiting
NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT06607185 2026-03-13
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
NCT04640480 2026-01-27
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
SN BioScience
Phase 1 Completed
NCT07325214 2026-01-12
Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer
IMGT Co., Ltd.
Phase NA Not yet recruiting
NCT06625320 2025-12-12
RASolute 302
Revolution Medicines, Inc.
Phase 3 Active not recruiting
NCT03184870 2025-10-09
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04581473 2025-06-05
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
CARsgen Therapeutics Co., Ltd.
Phase 1/2 Active not recruiting
NCT06538207 2025-02-06
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer
Ono Pharmaceutical Co. Ltd
Phase 1 Completed
NCT05859750 2024-12-16
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
Akeso
Phase 2 Recruiting
NCT06532344 2024-11-14
An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer
Ono Pharmaceutical Co. Ltd
Phase 1 Active not recruiting
NCT02231723 2023-11-18
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT04299880 2023-11-08
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT01803282 2020-06-02
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Completed
NCT01836432 2020-05-28
PILLAR
Lumos Pharma
Phase 3 Terminated
NCT02405585 2020-05-28
Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer
Lumos Pharma
Phase 2 Terminated
NCT03607643 2018-07-31
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
Leaf Vertical Inc.
Phase 1/2 Unknown